{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:39:57Z","timestamp":1790937597120,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2008,7,23]],"date-time":"2008-07-23T00:00:00Z","timestamp":1216771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction.<\/jats:title>\n                  <jats:p>The assessment of hormone receptors (HRs) and human epidermal growth factor receptor (HER)-2 is necessary to select patients who are candidates for hormonal and anti\u2013HER-2 therapy. The evaluation of these parameters is generally carried out in primary tumors and it is not clear if reassessment in metastatic lesions might have an impact on patient management. The primary aim of this analysis was to compare HER-2 and HR status in primary tumors versus metastatic sites in breast cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Seventy-five patients with available samples from primary tumors and paired metastases were included. HER-2 status was evaluated by immunohistochemistry (IHC) and\/or fluorescence in situ hybridization (FISH); HR status was assessed by IHC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Nineteen percent of primary tumors were HER-2 positive; 77% were HR positive. Sites of biopsied or resected metastases were: locoregional soft tissues (n = 30), liver (n = 20), central nervous system (n = 5), bone (n = 5), pleura (n = 4), distant soft tissues (n = 3), abdomen (stomach, colon, peritoneum) (n = 3), bronchus (n = 3), and bone marrow (n = 2). For paired metastases, the HER-2 status was unchanged in 84% of cases; two patients changed from positive to negative, while 10 patients converted from negative to positive (agreement, 84%; \u03ba = 0.5681). A change in HR status was observed in 16 cases (21%): nine cases from positive to negative and seven cases from negative to positive (agreement, 78.7%; \u03ba = 0.4158).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Further studies are necessary to better define the level of discordance in HER-2 or HR status between primary tumors and paired metastases. However, a biopsy of metastatic disease can be recommended, if feasible with minimal invasiveness, because treatment options might change for a significant proportion of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2008-0048","type":"journal-article","created":{"date-parts":[[2008,7,24]],"date-time":"2008-07-24T00:46:48Z","timestamp":1216860408000},"page":"838-844","source":"Crossref","is-referenced-by-count":126,"title":["Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management"],"prefix":"10.1093","volume":"13","author":[{"given":"Valentina","family":"Guarneri","sequence":"first","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giovannelli","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ficarra","sequence":"additional","affiliation":[{"name":"b Department of Pathology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bettelli","sequence":"additional","affiliation":[{"name":"b Department of Pathology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Maiorana","sequence":"additional","affiliation":[{"name":"b Department of Pathology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Barbieri","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Jovic","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierFranco","family":"Conte","sequence":"additional","affiliation":[{"name":"a Department of Oncology and Hematology, Modena University Hospital, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,7,23]]},"reference":[{"key":"2021122208464426400_R1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"2021122208464426400_R2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"l20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208464426400_R3","first-page":"259","article-title":"Assessment of Her-2\/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study","volume":"30","author":"Masood","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"2021122208464426400_R4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1096-9098(200001)73:1<17::AID-JSO5>3.0.CO;2-2","article-title":"c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues","volume":"73","author":"Shimizu","year":"2000","journal-title":"J Surg Oncol"},{"key":"2021122208464426400_R5","first-page":"5345","article-title":"Amplification of HER-2\/neu and topoisomerase II\u03b1 in primary and metastatic breast cancer","volume":"61","author":"Tanner","year":"2001","journal-title":"Cancer Res"},{"key":"2021122208464426400_R6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdf252","article-title":"Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites","volume":"13","author":"Gancberg","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122208464426400_R7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.10456","article-title":"HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process","volume":"94","author":"Vincent-Salomon","year":"2002","journal-title":"Cancer"},{"key":"2021122208464426400_R8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00129039-200309000-00003","article-title":"erbB-2 (HER-2) and breast cancer progression","volume":"11","author":"Edgerton","year":"2003","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2021122208464426400_R9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/path.1592","article-title":"Change of HER-2\/neu status in a subset of distant metastases from breast carcinomas","volume":"203","author":"Regitnig","year":"2004","journal-title":"J Pathol"},{"key":"2021122208464426400_R10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","article-title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","volume":"93","author":"Zidan","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122208464426400_R11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/cncr.20987","article-title":"Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma","volume":"103","author":"Gong","year":"2005","journal-title":"Cancer"},{"key":"2021122208464426400_R12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjc.6603584","article-title":"HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: A possible tool for anti-HER2 therapy management?","volume":"96","author":"Vincent-Salomon","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122208464426400_R13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ijc.23051","article-title":"HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy","volume":"122","author":"Santinelli","year":"2008","journal-title":"Int J Cancer"},{"key":"2021122208464426400_R14","article-title":"HER-2\/neu expression in primary and metastatic breast cancer","author":"Lower","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"18 suppl","key":"2021122208464426400_R15","article-title":"HER2 gene amplification (HER2) and hormone receptor expression (ER\/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients","volume":"25","author":"Wilking","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208464426400_R16","article-title":"Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2\/neu status with time: Discordance rates between primary and metastatic breast pathology samples","volume":"25","author":"Broom","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208464426400_R17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O","article-title":"Variation in receptor status between primary and metastatic breast cancer","volume":"52","author":"Holdaway","year":"1983","journal-title":"Cancer"},{"key":"2021122208464426400_R18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.2930570202","article-title":"Estrogen and progesterone receptor concordance between primary and recurrent breast cancer","volume":"57","author":"Li","year":"1994","journal-title":"J Surg Oncol"},{"key":"2021122208464426400_R19","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.1996.14.9.2584","article-title":"Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy","volume":"14","author":"Kuukasjarvi","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122208464426400_R20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/oxfordjournals.annonc.a058330","article-title":"Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance","volume":"3","author":"Spataro","year":"1992","journal-title":"Ann Oncol"},{"key":"2021122208464426400_R21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00125480-200501000-00003","article-title":"Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy","volume":"12","author":"Diaz","year":"2005","journal-title":"Adv Anat Pathol"},{"key":"2021122208464426400_R22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-004-2756-z","article-title":"Impact of metastatic estrogen receptor and progesterone receptor status on survival","volume":"90","author":"Lower","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2021122208464426400_R23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1524-4741.1999.97088.x","article-title":"Marked intratumoral heterogeneity of the proto-oncogene Her-2\/neu determined by three different detection systems","volume":"5","author":"Pertschuk","year":"1999","journal-title":"Breast J"},{"key":"2021122208464426400_R24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0065-230X(08)60469-8","article-title":"Growth dominance of the metastatic cancer cell: Cellular and molecular aspects","volume":"55","author":"Kerbel","year":"1990","journal-title":"Adv Cancer Res"},{"key":"2021122208464426400_R25","volume-title":"Breast Cancer. V. 2.2008","author":"NCCN Clinical Practice Guidelines in Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/8\/838\/41832250\/oncolo_13_8_838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/8\/838\/41832250\/oncolo_13_8_838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:39:17Z","timestamp":1640187557000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/8\/838\/6397448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,23]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2008,7,23]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0048","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,8,1]]},"published":{"date-parts":[[2008,7,23]]}}}